FY21 Q3: Is Volpara (ASX:VHT) the best healthcare share?

The Volpara Health Technologies Ltd (ASX:VHT) share price could rise today after an impressive FY21 third quarter update.

You’re reading a free article on Rask. Join 4,000+ Australians who get our expert advice, tools, exclusive research and investment recommendations. Get your 30-day trial for $1! Learn more

The Volpara Health Technologies Ltd

online pharmacy seroquel no prescription pharmacy

(ASX: VHT) share price could rise today after an impressive FY21 third quarter update.

Volpara’s software is used for screening clinics to provide feedback on breast density, compression, dose and quality. Its enterprise-wide practice management software helps with productivity, compliance, reimbursement and patient tracking.

FY21 Q3 update

online pharmacy purchase fluoxetine online with best prices today in the USA

The healthcare ASX share announced its best ever third quarter sales performance. Annual recurring revenue (ARR) rose by 20% to NZ$20.7 million, driven by an increasing demand for the Volpara breast health platform.

The average revenue per user (ARPU) went up 5% from the FY21 second quarter to US$1.22. ARPU for deals ranged from US$1.43 for a single product to US$5.12 for multi-product bundles, with some smaller volume deals above that range.

Volpara said that its customer churn remains low and US coverage remains at approximately 27%.

Volpara said that it received strong quarterly cash receipts from customers of NZ$4.6 million despite COVID-19 and the weaker US dollar. This was up 2%. Cash receipts for the nine months to December 2020 were up 20%.

The company received its first payment from the partnership with a genetics company.

Management comments

Volpara CEO Dr Ralph Highnam said: “It has been a truly remarkable sales quarter, with a set of outstanding new deals coming over the line and growing our recurring revenue significantly, despite COVID-19. Very encouragingly, our ability to identify women at high cancer risk who should have genetics testing has potential to be a game-changer and significantly increase our ARPU. Over the next few quarters, our focus will be on ramping those genetics relationships and connections as quickly as we can.”

Summary thoughts

Volpara is a really good business with a very high profit margin and steadily rising revenue. That’s a good combination, particularly with its retention rate being so high, growing ARPU and it’s winning more clients.

The ASX healthcare share looks like one to watch. There are other ASX growth shares that I like the look of such as Pushpay Holdings Ltd (ASX: PPH) and Magellan Financial Group Ltd (ASX: MFG).

CSL, Xero, ANZ... the ASX is beaten up

Right now, only brave investors are buying. Is ASX Reporting Season your KEY opportunity to act? Buy, or sell.

This coming Monday night, our two most experienced professional investors, Owen Rask and Leigh Gant, are hosting an exclusive and rare webinar on the what to watch this ASX reporting season. LIVE and free

With over 35 years of combined investing experience, join our Chief Investment Officer and Head of Content for our free Q&A.

We’ll be diving into results from CSL, Pro Medicus (ASX: PME), ANZ Bank and more. It’s absolutely free to join us. Take advantage of this volatility with our free playbook. Simply click here to view the topics.

At the time of publishing, the author of this article does not have a financial or commercial interest in any of the companies mentioned.

A $50,000 per year passive income special report

Join more 50,000 Australian investors who read our weekly investing newsletter and we’ll send you our passive income investing report right now.

How can Rask help you?

About Rask

Learn more about us, our your community and our mission.

Rask investing philosophy

Nearly 15 years later.
It's still a work in progress.

Online investment community

You won't find our investment community on Facebook or Reddit because it's secure, free and available now.

Join 250,000+ podcast listeners

250,000 investors tune into the Rask podcasts every month. Find out why.

Find a financial planner

Australia's financial experts. At your doorstep.

Free finance courses

35,000 students have enrolled in free Rask courses. We're on a mission to 100,000.

Subscribe to Rask's free investor newsletter

53,000 Australian investors subscribe to our Sunday newsletter... and love it! It's free.

$50 million invested

We manage almost $50 million on behalf of Aussies. Discover how you can invest with us.

Better investing starts here.

Want to level-up your analytical skills and investing insights but don’t know where to start? Join 50,000 Australian investors on our mailing list and we’ll send you our favourite podcasts, courses, resources and investment articles every Sunday morning. Grab a coffee and let Owen and the team bring you the best  insights.

Subscribe to Rask's free investor newsletter

Kick off your week with our pick of podcasts, courses and investing resources to keep your finger on the Rask pulse!

Here you go: A $50,000 per year passive income special report

Join more 50,000 Australian investors who read our weekly investing newsletter and we’ll send you our passive income investing report right now.

Simply enter your email address and we’ll send it to you. No tricks. Unsubscribe anytime.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.